Recent Advances in the Discovery and Preclinical Testing of Novel Compounds for the Prevention and/or Treatment of Alcohol Use Disorders

Alcoholism: Clinical and Experimental Research

Volumn 37, Issue 1, 2013, Pages 8-15

  Davies, Daryl L ^a   Bortolato, Marco ^a   Finn, Deborah A ^b   Ramaker, Marcia J ^b   Barak, Segev ^c   Ron, Dorit ^c   Liang, Jing ^d   Olsen, Richard W ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dihydromyricetin; Ganaxolone; Glial cell line derived neurotrophic factor; Ivermectin; Purinergic receptors

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; ALCOHOL; AMPELOPSIN; GABOXADOL; GANAXOLONE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IVERMECTIN; NEUROSTEROID; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ALCOHOL METABOLISM; ALCOHOL TOLERANCE; ALCOHOL USE DISORDER; ALCOHOLISM; AUTOREGULATION; BEHAVIOR CHANGE; CHINESE MEDICINE; DRUG TOLERABILITY; GABAERGIC SYSTEM; HUMAN; NEUROCHEMISTRY; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; SHORT SURVEY; SOCIOECONOMICS; STIMULUS RESPONSE; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

EID: 84871943577     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2012.01846.x     Document Type: Review

References (70)

1. Airaksinen MS, Saarma M (2002) The GDNF family: signaling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394.
2. Airavaara M, Planken A, Gaddnas H, Piepponen TP, Saarma M, Ahtee L (2004) Increased extracellular dopamine concentrations and FosB/DeltaFosB expression in striatal brain areas of heterozygous GDNF knockout mice. Eur J Neurosci 20:2336-2344.
3. Arolfo MP, Overstreet DH, Yao L, Fan P, Lawrence AJ, Tao G, Keung WM, Vallee BL, Olive MF, Gass JT, Rubin E, Anni H, Hodge CW, Besheer J, Zablocki J, Leung K, Blackburn BK, Lange LG, Diamond I (2009) Suppression of heavy drinking and alcohol seeking by a selective ALDH-2 inhibitor. Alcohol Clin Exp Res 33:1935-1944.
4. Asatryan L, Nam HW, Lee MR, Thakkar MM, Dar MS, Davies DL, Choi DS (2011) Implication of the purinergic system in alcohol use disorders. Alcohol Clin Exp Res 35:584-594.
5. Asatryan L, Popova M, Perkins DI, Trudell JR, Alkana RL, Davies DL (2010) Ivermectin antagonizes ethanol inhibition in P2X4 receptors. Pharmacol Exp Ther 334:720-728.
6. Barak S, Ahmadiantehrani S, Kharazia V, Ron D (2011a) Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumption. Transl Psychiatry 1:1-9.
7. Barak S, Carnicella S, Yowell QV, Ron D (2011b) Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking. J Neurosci 31:9885-9894.
8. (A) receptor. Nat Rev Neurosci 6:565-575.
9. Besheer J, Lindsay TG, O'Buckley TK, Hodge CW, Morrow AL (2010) Pregnenolone and ganaxolone reduce operant ethanol self-administration in alcohol-preferring p rats. Alcohol Clin Exp Res 34:2044-2052.
10. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD (2011) Economic costs of excessive alcohol consumption in the U.S., 2006. Am J Prev Med 41:516-524.
11. Bouza C, Angeles M, Munoz A, Amate JM (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99:811-828.
12. A receptors. Mol Pharmacol 63:53-64.
13. Carnicella S, Ahmadiantehrani S, He DY, Nielsen CK, Bartlett SE, Janak PH, Ron D (2009a) Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor. Biol Psychiatry 66:146-153.
14. Carnicella S, Ahmadiantehrani S, Janak PH, Ron D (2009b) GDNF is an endogenous negative regulator of ethanol-mediated reward and of ethanol consumption after a period of abstinence. Alcohol Clin Exp Res 33:1012-1024.
15. Carnicella S, Amamoto R, Ron D (2009c) Excessive alcohol consumption is blocked by glial cell line-derived neurotrophic factor. Alcohol 43:35-43.
16. Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D (2008) GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci USA 105:8114-8119.
17. Carnicella S, Ron D (2009) GDNF-a potential target to treat addiction. Pharmacol Ther 122:9-18.
18. (A) receptor modulation of the rewarding and aversive effects of ethanol. Alcohol 26:131-143.
19. Colao A, Di Sarno A, Guerra E, De Leo M, Mentone A, Lombardi G (2006) Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab 2:200-210.
20. Colombo G, Orrù A, Lai P, Cabras C, Maccioni P, Rubio M, Gessa GL, Carai MA (2007) The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol 36:102-112.
21. Cremers T, Ebert B (2007) Plasma and CNS concentrations of Gaboxadol in rats following subcutaneous administration. Eur J Pharmacol 562:47-52.
22. Davies DL, Kochegarov AA, Kuo ST, Kulkarni AA, Woodward JJ, King BF, Alkana RL (2005) Ethanol differentially affects ATP-gated P2X(3) and P2X(4) receptor subtypes expressed in Xenopus oocytes. Neuropharmacology 49:243-253.
23. Davies DL, Machu TK, Guo Y, Alkana RL (2002) Ethanol sensitivity in ATP-gated P2X receptors is subunit dependent. Alcohol Clin Exp Res 26:773-778.
24. Diana M, Brodie M, Muntoni A, Puddu MC, Pillolla G, Steffensen S, Spiga S, Little HJ (2003) Enduring effects of chronic ethanol in the CNS: basis for alcoholism. Alcohol Clin Exp Res 27:354-361.
25. Diana M, Pistis M, Carboni S, Gessa GL, Rossetti ZL (1993) Profound decrement of mesolimbic dopaminergic neuronal activity during ethanol withdrawal syndrome in rats: electrophysiological and biochemical evidence. Proc Natl Acad Sci USA 90:7966-7969.
26. Finn DA, Beckley EH, Kaufman KR, Ford MM (2010) Manipulation of GABAergic steroids: sex differences in the effects on alcohol drinking- and withdrawal-related behaviors. Horm Behav 57:12-22.
27. Finn DA, Mark GP, Fretwell AM, Gililland-Kaufman KR, Strong MN, Ford MM (2008) Reinstatement of ethanol and sucrose seeking by the neurosteroid allopregnanolone in C57BL/6 mice. Psychopharmacology 201:423-433.
28. Ford MM, Beckley EH, Nickel JD, Eddy S, Finn DA (2008) Ethanol intake patterns in female mice: influence of allopregnanolone and the inhibition of its synthesis. Drug Alcohol Depend 97:73-85.
29. Ford MM, Mark GP, Nickel JD, Phillips TJ, Finn DA (2007) Allopregnanolone influences the consummatory processes that govern ethanol drinking in C57BL/6J mice. Behav Brain Res 179:265-272.
30. (A) receptors differentially modulate ethanol intake patterns in male C57BL/6J mice. Alcohol Clin Exp Res 29:1630-1640.
31. Geary TG (2005) Ivermectin 20 years on: maturation of a wonder drug. Trends Parasitol 21:530-532.
32. Gewiss M, Heidbreder C, Opsomer L, Durbin P, De Witte P (1991) Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol 26:129-137.
33. Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L (2010) Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci Biobehav Rev 35:157-171.
34. Gonzales RA, Job MO, Doyon WM (2004) The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol Ther 103:121-146.
35. Grant BF, Dawson DA, Stinson FS, Chou P, Dufour MC, Pickering RP (2004) The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 74:223-234.
36. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC (2002) Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42:1122-1133.
37. Harwood HJ (2000) Updating estimates of the economic costs of alcohol abuse in the United States: Estimates, update methods, and data. Contract No. N01-AA-7-1010 (The Lewin Group). National Institute on Alcohol Abuse and Alcoholism, Rockville, MD.
38. Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111:855-876.
39. A receptor. J Med Chem 40:61-72.
40. Howard RJ, Slesinger PA, Davies DL, Das J, Trudell JR, Harris RA (2011) Alcohol-binding sites in distinct brain proteins: the quest for atomic level resolution. Alcohol Clin Exp Res 35:1561-1573.
41. Janak PH, Gill TM (2003) Comparison of the effects of allopregnanolone with direct GABAergic agonists on ethanol self-administration with and without concurrently available sucrose. Alcohol 30:1-7.
42. Johnson B (2010) Medication treatment of different types of alcoholism. Am J Psychiatry 167:630-639.
43. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift R (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641-1651.
44. (A) receptor subtypes. Biochem Pharmacol 82:1971-1983.
45. Khakh BS, Proctor WR, Dunwiddie TV, Labarca C, Lester HA (1999) Allosteric control of gating and kinetics at P2X4 receptor channels. J Neurosci 19:7289-7299.
46. Kimpel MW, Strother WN, McClintick JN, Carr LG, Liang T, Edenberg HJ, McBride WJ (2007) Functional gene expression differences between inbred alcohol-preferring and -non-preferring rats in five brain regions. Alcohol 41:95-132.
47. Kosten TA (2011) Pharmacologically targeting the p2rx4 gene on maintenance and reinstatement of alcohol self-administration in rats. Pharmacol Biochem Behav 98:533-538.
48. A receptor plasticity after ethanol intoxication. J Neurosci 27:12367-12377.
49. A receptors. J Neurosci 26:1749-1758.
50. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132.
51. Lukas SE, Penetar D, Berko J, Vicens L, Palmer C, Mallya G, Macklin EA, Lee DY (2005) An extract of the Chinese herbal root kudzu reduces alcohol drinking by heavy drinkers in a naturalistic setting. Alcohol Clin Exp Res 29:756-762.
52. (A) receptors. J Neurophysiol 106:2057-2064.
53. Molinari G, Soloneski S, Larramendy ML (2010) New ventures in the genotoxic and cytotoxic effects of macrocyclic lactones, Abamectin and Ivermectin. Cyogenet Genome Res 128:37-45.
54. Moore EM, Serio KM, Goldfarb KJ, Stepanovska S, Linsenbardt DN, Boehm SL II (2007) GABAergic modulation of binge-like ethanol intake in C57BL/6J mice. Pharmacol Biochem Behav 88:105-113.
55. Nie H, Janak PH (2003) Comparison of reinstatement of ethanol- and sucrose-seeking by conditioned stimuli and priming injections of allopregnanolone after extinction in rats. Psychopharmacology 168:222-228.
56. A receptor plasticity in alcohol withdrawal. Ch. 43, in Jasper's Basic Mechanisms of the Epilepsies, Vol. 4. (Noebels J, Avoli M, Rogawski M, Olsen RW, Delgado-Escueta AV, eds), pp 562-573. Oxford University Press, New York.
57. Omura S (2008) Ivermectin: 25 years and still going strong. Int J Antimicrobial Agents 31:91-98.
58. Paul SM (2006) Alcohol-sensitive GABA receptors and alcohol antagonists. Proc Natl Acad Sci USA 103:8307-8308.
59. Popova M, Asatryan L, Ostrovskaya O, Wyatt RL, Li K, Alkana RL, Davies DL (2010) A point mutation in the ectodomain-transmembrane 2 interface eliminates the inhibitory effects of ethanol in P2X4 receptors. J Neurochem 112:307-317.
60. (A) receptor with ganaxolone, finasteride, and gaboxadol. Alcohol Clin Exp Res 35:1994-2007.
61. Rossetti ZL, Melis F, Carboni S, Diana M, Gessa GL (1992) Alcohol withdrawal in rats is associated with a marked fall in extraneuronal dopamine. Alcohol Clin Exp Res 16:529-532.
62. Shen RY, Choong KC, Thompson AC (2007) Long-term reduction in ventral tegmental area dopamine neuron population activity following repeated stimulant or ethanol treatment. Biol Psychiatry 61:93-100.
63. Shen Y, Lindemeyer AK, Gonzalez C, Shao XM, Spigelman I, Olsen RW, Liang J (2012) Dihydromyricetin as a novel anti-alcohol intoxication medication. J Neurosci 32:390-401.
64. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 104:12518-12523.
65. Tabakoff B, Saba L, Printz M, Flodman P, Hodgkinson C, Goldman D, Koob G, Richardson H, Kechris K, Bell RL, Hübner N, Heinig M, Pravenec M, Mangion M, Legault L, Dongier M, Conigrave KM, Whitfield JB, Saunders JB, Grant B, Hoffman PL (2009) Genetical genomic determinants of alcohol consumption in rats and humans. BMC Biol 7:70.
66. A receptors are reversed by the behavioral alcohol antagonist Ro15-4513. Proc Natl Acad Sci USA 103:8540-8545.
67. Wang J, Carnicella S, Ahmadiantehrani S, He DY, Barak S, Kharazia V, Ben Hamida S, Zapata A, Shippenberg TS, Ron D (2010) Nucleus accumbens-derived glial cell line-derived neurotrophic factor is a retrograde enhancer of dopaminergic tone in the mesocorticolimbic system. J Neurosci 30:14502-14512.
68. Weiss F, Parsons LH, Schulteis G, Hyytia P, Lorang MT, Bloom FE, Koob GF (1996) Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J Neurosci 16:3474-3485.
69. Xiong K, Hu XQ, Stewart RR, Weight FF, Li C (2005) The mechanism by which ethanol inhibits rat P2X4 receptors is altered by mutation of histidine 241. Br J Pharmacol 145:576-586.
70. Yardley MM, Wyatt L, Khoja S, Asatryan L, Ramaker MJ, Finn DA, Alkana RL, Huynh N, Louie SG, Petasis NA, Bortolato M, Davies DL (in press) Ivermectin reduces alcohol intake and preference in mice. Neuropharmacology doi: 10.1016/j.neuropharm.2012.03.014 [Epub ahead of print].